Latest News for: ALFA

Edit

CNMV Warning to the Public on Unregistered Firm (HTTPS://ALFALESURE.COM/ (CLON) ALFA VALOR INVESTMENT (CLON) ALFA VALOR INVESTMENT LTD (CLON) ALFA VALOR INVESTMENTS LTD (CLON)) (CNMV - Comisión Nacional del Mercado de Valores)

Public Technologies 23 Feb 2026
https.//alfalesure.com/ (CLONE) ALFA VALOR INVESTMENT (CLONE) ALFA VALOR INVESTMENT LTD (CLONE) ALFA VALOR INVESTMENTS LTD (CLONE). Is not related to ALFA VALOR INVERSIONES EAF, S.A., and its website, ...
Edit

Machos Alfa, el s�ndrome de la hoja en blanco (y la pantalla en negro)

Clarin 21 Feb 2026
Cuando termina una serie, el vac�o se parece demasiado a la hoja en blanco del periodista. �qu� historia necesitamos ahora? ....
Edit

Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC

Hastings Tribune 20 Feb 2026
Phase 1b expansion cohort data evaluating 2000mg of ficerafusp alfa every other week in combination with pembrolizumab in 1L HPV-negative R/M HNSCC patients demonstrate rapid, deep and durable ...
Edit

Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports ...

Nasdaq Globe Newswire 19 Feb 2026
Phase 1b expansion cohort data evaluating 2000mg of ficerafusp alfa every other week in combination with pembrolizumab in 1L HPV-negative R/M HNSCC patients demonstrate rapid, deep and durable ...
Edit

MHNCS 2026 Oral Presentation: Ficerafusp alfa (2000mg Q2W) and pembrolizumab in HPV-negative first-line recurrent/metastatic head and neck squamous cell carcinoma (Bicara Therapeutics Inc)

Public Technologies 19 Feb 2026
) Ficerafusp alfa (2000 mg Q2W) and pembrolizumab in HPV-negative first-line recurrent/metastatic head and neck squamous cell carcinoma. Dan P. Zandberg, John M. Kaczmar, Assuntina G. Sacco, Glenn J ... Describe ficerafusp alfa's unique mechanism of action.
Edit

Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of Less Frequent Dosing Regimen (Form 8-K) (Bicara Therapeutics Inc)

Public Technologies 19 Feb 2026
) Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of Less Frequent Dosing Regimen ... About Ficerafusp Alfa ... Specifically, ficerafusp alfa combines two clinically validated targets.
Edit

Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of Less Frequent Dosing Regimen (Bicara Therapeutics Inc)

Public Technologies 19 Feb 2026
Phase 1b expansion cohort data evaluating 2000mg of ficerafusp alfa every other week in combination with pembrolizumab in 1L HPV-negative R/M HNSCC patients demonstrate rapid, deep and durable responses with generally well-tolerated safety profile.
Edit

P.R-(ALFA)-2026-02-15 (Jordan Investment and Multiple Transport PSC)

Public Technologies 15 Feb 2026
). The text version of this document is not available ... Attachments Original document Permalink.
×